NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
Clinical Trials
7 trialsNCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06768255 2025-01-10
mCRPC
Fudan University
Phase 3 Not yet recruiting
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT04139772 2023-03-24
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
National Cancer Institute, Naples
Phase 3 Unknown